NCT06730802

Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII)

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, randomized controlled study to investigate whether early offering PCSK9 inhibitor can protect against negative inflammatory response and organ dysfunction after coronary artery bypass grafting (CABG). Subjects with myocardial ischaemic syndromes (MIS) will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy, while the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later. Six month after CABG, CRP will be used to evaluate inflammation, and echocardiography and coronary CTA will be used to evaluate cardiovascular function.

Conditions

• Myocardial Ischaemic Syndrome
• Coronary Heart Disease

Interventions

Type	Name	Description
DRUG	PCSK9 inhibitor	the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.
DRUG	Statin	the control group will receive standard statin therapy.

Timeline

• Start date: 2025-01-01
• Primary completion: 2026-12-31
• Completion: 2026-12-31
• First posted: 2024-12-12
• Last updated: 2024-12-12

Locations

2 sites across 1 country: China